blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2569267

EP2569267 - IMPROVED METHODS FOR PREPARING SQUALENE [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  17.02.2017
Database last updated on 20.09.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2013/12]
Inventor(s)01 / HORA, Maninder
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, CA 94158 / US
 [2013/12]
Representative(s)Marshall, Cameron John
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2013/52]
Former [2013/12]Marshall, Cameron John
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Application number, filing date11738802.512.05.2011
[2017/12]
WO2011IB01397
Priority number, dateUS20100395448P12.05.2010         Original published format: US 395448 P
[2013/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011141819
Date:17.11.2011
Language:EN
[2011/46]
Type: A1 Application with search report 
No.:EP2569267
Date:20.03.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 17.11.2011 takes the place of the publication of the European patent application.
[2013/12]
Type: B1 Patent specification 
No.:EP2569267
Date:25.12.2013
Language:EN
[2013/52]
Type: B2 New European patent specification 
No.:EP2569267
Date:22.03.2017
Language:EN
[2017/12]
Search report(s)International search report - published on:EP17.11.2011
ClassificationIPC:A61K39/00, A61K39/145, B01D3/10, C12N7/00, A61K39/39, A61K47/06, C07C7/04, A61K9/107
[2016/30]
CPC:
A61K39/39 (EP,KR,US); C07C11/21 (KR); A61K31/01 (KR);
A61K39/145 (KR,US); A61K47/06 (EP,KR,US); A61K47/10 (KR);
A61K47/24 (KR); A61K9/107 (EP,KR,US); A61P31/00 (EP);
A61P31/16 (EP); B01D3/10 (KR,US); B01D3/143 (US);
B01L3/10 (US); C07C7/04 (EP,KR,US); C12N7/00 (KR,US);
A61K2039/55566 (EP,US); C12N2760/16034 (US) (-)
C-Set:
C07C7/04, C07C11/21 (EP,US)
Former IPC [2013/12]C07C11/21, C07C7/04, A61K9/107, A61K31/01, A61K39/39, A61K47/06, A61P31/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/12]
TitleGerman:VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON SQUALEN[2013/12]
English:IMPROVED METHODS FOR PREPARING SQUALENE[2013/12]
French:PROCÉDÉS AMÉLIORÉS D'ÉLABORATION DE SQUALÈNE[2013/12]
Entry into regional phase11.09.2012National basic fee paid 
11.09.2012Designation fee(s) paid 
11.09.2012Examination fee paid 
Examination procedure06.03.2012Request for preliminary examination filed
International Preliminary Examining Authority: EP
11.09.2012Examination requested  [2013/12]
15.02.2013Amendment by applicant (claims and/or description)
12.08.2013Communication of intention to grant the patent
31.10.2013Fee for grant paid
31.10.2013Fee for publishing/printing paid
Divisional application(s)EP13164769.5  / EP2620423
EP16176832.0  / EP3103784
EP19151232.6  / EP3489211
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  12.08.2013
Opposition(s)Opponent(s)01  25.09.2014  01.10.2014  ADMISSIBLE
GLAXO SMITHKLINE BIOLOGICALS S.A.
Rue de l'Institut 89
1330 Rixensart / BE
Opponent's representative
Furstoss, Olivia Aline
GSK
W23-F3
20, avenue Fleming
1300 Wavre / BE
 [N/P]
Former [2016/09]
Opponent(s)01  25.09.2014  01.10.2014  ADMISSIBLE
GLAXO SMITHKLINE BIOLOGICALS S.A.
Rue de l'Institut 89
1330 Rixensart / BE
Opponent's representative
Furstoss, Olivia Aline
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex, TW8 9GS / GB
Former [2016/08]
Opponent(s)01  25.09.2014  01.10.2014  ADMISSIBLE
GLAXO SMITHKLINE BIOLOGICALS S.A.
Rue de l'Institut 89
1330 Rixensart / BE
Opponent's representative
Dalton, Marcus Jonathan William
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Former [2014/45]
Opponent(s)01  25.09.2014  01.10.2014  ADMISSIBLE
GLAXO SMITHKLINE BIOLOGICALS S.A.
Rue de l'Institut 89
1330 Rixensart / BE
Opponent's representative
Robertson, James Stuart
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
03.11.2014Invitation to proprietor to file observations on the notice of opposition
08.05.2015Reply of patent proprietor to notice(s) of opposition
23.05.2016Legal effect of interlocutory decision in opposition
23.05.2016Date of oral proceedings
14.07.2016Despatch of interlocutory decision in opposition
14.07.2016Despatch of minutes of oral proceedings
15.11.2016Despatch of communication that the patent will be maintained as amended
23.01.2017Fee for printing new specification paid
Fees paidRenewal fee
10.05.2013Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.05.2011
AL25.12.2013
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MK25.12.2013
MT25.12.2013
RS25.12.2013
SK25.12.2013
SM25.12.2013
NO25.03.2014
GR26.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
[2018/46]
Former [2018/31]HU12.05.2011
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MK25.12.2013
MT25.12.2013
RS25.12.2013
SK25.12.2013
SM25.12.2013
NO25.03.2014
GR26.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
Former [2017/42]HU12.05.2011
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
RS25.12.2013
SK25.12.2013
SM25.12.2013
NO25.03.2014
GR26.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
Former [2016/32]HU12.05.2011
BG25.12.2013
CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
RS25.12.2013
SK25.12.2013
SM25.12.2013
NO25.03.2014
GR26.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
Former [2016/28]BG25.12.2013
CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
RS25.12.2013
SK25.12.2013
SM25.12.2013
NO25.03.2014
GR26.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
Former [2016/22]CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
RS25.12.2013
SK25.12.2013
SM25.12.2013
NO25.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
Former [2016/16]CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
RS25.12.2013
SK25.12.2013
NO25.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
Former [2015/21]CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
RS25.12.2013
SK25.12.2013
NO25.03.2014
IS25.04.2014
PT28.04.2014
IE12.05.2014
LU12.05.2014
Former [2015/09]CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
RS25.12.2013
SK25.12.2013
NO25.03.2014
IS25.04.2014
PT28.04.2014
LU12.05.2014
Former [2015/04]CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
RS25.12.2013
SK25.12.2013
NO25.03.2014
IS25.04.2014
PT28.04.2014
LU12.05.2014
Former [2014/48]CY25.12.2013
DK25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
RS25.12.2013
SK25.12.2013
NO25.03.2014
IS25.04.2014
PT28.04.2014
Former [2014/37]CY25.12.2013
EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
RS25.12.2013
SK25.12.2013
NO25.03.2014
IS25.04.2014
PT28.04.2014
Former [2014/36]EE25.12.2013
FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
RS25.12.2013
NO25.03.2014
IS25.04.2014
Former [2014/25]FI25.12.2013
HR25.12.2013
LT25.12.2013
LV25.12.2013
RS25.12.2013
NO25.03.2014
Former [2014/24]FI25.12.2013
HR25.12.2013
LT25.12.2013
RS25.12.2013
NO25.03.2014
Former [2014/23]FI25.12.2013
HR25.12.2013
LT25.12.2013
NO25.03.2014
Former [2014/22]FI25.12.2013
LT25.12.2013
NO25.03.2014
Former [2014/20]LT25.12.2013
NO25.03.2014
Cited inInternational search[I]JPH06116171  (NIPPON FINE CHEMICAL CO) [I] 1-11 * paragraphs [0017] , [0018] * * abstract *;
 [XDI]WO2007052155  (NOVARTIS VACCINES & DIAGNOSTIC [IT], et al) [XD] 12,13,17,20-23 * claims 1,18 * * page 16, paragraph 7 * * paragraph 9 - page 19, paragraph 5 * [I] 14-16,18,19;
 [IA]CN101597204  (UNIV TIANJIN [CN]) [I] 2-11 * examples 1-3 *[A] 1;
 [IA]WO2010004193  (SOPHIM [FR], et al) [I] 2-11 * page 32, line 23 - page 33, line 11; example 7 * * page 33, line 15 - line 33; example 8 * [A] 1
Examination   - SULI J ET AL, "Experimental squalene adjuvant - I. Preparation and testing of its effectiveness", VACCINE, ELSEVIER LTD, GB, (20040903), vol. 22, no. 25-26, doi:10.1016/J.VACCINE.2004.02.023, ISSN 0264-410X, pages 3464 - 3469, XP004526924

DOI:   http://dx.doi.org/10.1016/j.vaccine.2004.02.023
by applicantUS4060082
 EP0139417
 WO9014837
 EP0520618
 WO9737000
 WO9801174
 WO9907820
 US5971953
 WO0007647
 WO0122992
 WO02097072
 US6692468
 WO2005089837
 US2007014805
 WO2007052155
 US2007191314
 WO2008043774
    - BORUCINSKA, FRASCA, J FISH DISEASES, (2002), vol. 25, pages 287 - 98
    - BERTONE ET AL., J FISH DISEASES, (1996), vol. 19, pages 429 - 34
    - BRIONES ET AL., J VET MED B, (1998), vol. 45, pages 443 - 5
    - PODDA, DEL GIUDICE, EXPERT REV VACCINES, (2003), vol. 2, pages 197 - 203
    - PODDA, VACCINE, (2001), vol. 19, pages 2673 - 2680
    - Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series, vol. 42
    - SULI ET AL., VACCINE, (2004), vol. 22, no. 25-26, pages 3464 - 9
    - HOFFMANN ET AL., VACCINE, (2002), vol. 20, pages 3165 - 3170
    - SUBBARAO ET AL., VIROLOGY, (2003), vol. 305, pages 192 - 200
    - LIU ET AL., VIROLOGY, (2003), vol. 314, pages 580 - 590
    - OZAKIET, J. VIROL, (2004), vol. 78, pages 1851 - 1857
    - OZAKI ET AL., J: J.VIROL., (2004), vol. 78, pages 1851 - 1857
    - WEBBY ET AL., LANCET, (2004), vol. 363, pages 1099 - 1103
    - BRANDS ET AL., DEV BIOL STAND, (1999), vol. 98, pages 93 - 100
    - HALPERIN ET AL., VACCINE, (2002), vol. 20, pages 1240 - 7
    - TREE ET AL., VACCINE, (2001), vol. 19, pages 3444 - 50
    - KISTNER ET AL., VACCINE, (1998), vol. 16, pages 960 - 8
    - KISTNER ET AL., DEV BIOL STAND, (1999), vol. 98, pages 101 - 110
    - BRUHL ET AL., VACCINE, (2000), vol. 19, pages 1149 - 58
    - PAU ET AL., VACCINE, (2001), vol. 19, pages 2716 - 21
    - HEHME ET AL., VIRUS RES., (2004), vol. 103, no. 1-2, pages 163 - 71
    - TREANOR ET AL., J INFECT DIS, (1996), vol. 173, pages 1467 - 70
    - KEITEL ET AL., CLIN DIAGN LAB IMMUNOL, (1996), vol. 3, pages 507 - 10
    - WILLIAMSON ET AL., INFECTION AND IMMUNITY, (2006), vol. 74, pages 961 - 7
    - LOUKAS ET AL., PLOS MED, (2005), vol. 2, no. 10, page E295
    - HARPER ET AL., LANCET, (2004), vol. 364, no. 9447, pages 1757 - 65
    - J TOXICOL CLIN TOXICOL, (2001), vol. 39, pages 85 - 100
    - DEMICHELI ET AL., VACCINE, (1998), vol. 16, pages 880 - 884
    - STEPANOV ET AL., J BIOTECHNOL, (1996), vol. 44, pages 155 - 160
    - BANZHOFF, IMMUNOLOGY LETTERS, (2000), vol. 71, pages 91 - 96
    - GREENBAUM ET AL., VACCINE, (2004), vol. 22, pages 2566 - 77
    - ZURBRIGGEN ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 295 - 304
    - PIASCIK, JAM PHARM ASSOC (WASH DC)., (2003), vol. 43, pages 728 - 30
    - MANN ET AL., VACCINE, (2004), vol. 22, pages 2425 - 9
    - HALPERIN ET AL., AM J PUBLIC HEALTH, (1979), vol. 69, pages 1247 - 50
    - HERBERT ET AL., J INFECT DIS, (1979), vol. 140, pages 234 - 8
    - CHEN ET AL., VACCINE, (2003), vol. 21, pages 2830 - 6
OppositionCN101830770
 JP2000191550
 CN1810744
 WO2008142175
 JPH06116171
 JP3484227B
 CN101597204
 WO2010092479
    - Focetria TM EPAR - Assessment Report - Variation
    - Internet page on "Vacuum distillation" (page available 23 April 2010) http://en.wikipedia.org/w/index.php?title=Vacuum distillation&oldid=288287808
    - PIETSCH A. ET AL, "Concentration of squalene from shark liver oil by short-path distillation", EUR. J. LIPID SCI. TECHNOL., (2007), vol. 109, doi:doi:10.1002/ejlt.200700039, pages 1077 - 1082, XP055055506

DOI:   http://dx.doi.org/10.1002/ejlt.200700039
    - CN 101830770 A (ENGLISH TRANSLATION), & CN101830770 A 00000000
    - MAKIDON P.E. ET AL, "Characterization of Stability and Nasal Delivery Systems for Immunization with Nanoemulsion-Based Vaccines", JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, (2010), vol. 23, no. 2, doi:doi:10.1089/jamp.2009.0766, pages 77 - 89, XP055114283

DOI:   http://dx.doi.org/10.1089/jamp.2009.0766
    - OTT G. ET AL, Methods in Molecular Medicine, TOTOWA NJ, HUMAN PRESS, (2000), vol. 42, pages 211 - 228
    - OTT G. ET AL, Vaccine Design, the Subunit and Adjuvant Approach Pharmaceutical Biotechnology, (1995), vol. 6, pages 277 - 296
    - BRITO J.A. ET AL, "An alternative renewable of squalene for use in emulsion adjuvants", VACCINE, (2011), vol. 29, doi:doi:10.1016/j.vaccine.2011.06.067, pages 6262 - 6268, XP028263655

DOI:   http://dx.doi.org/10.1016/j.vaccine.2011.06.067
    - JP 2000191550 A (ORIGINAL DOCUMENT), & JP2000191550 A 00000000
    - re-translation of sections of D13a
    - CN 1810744A (Original document), & CN1810744 A 00000000
    - JP3484227 B2 (Original document)
    - internet page, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hu man/medicines/000710/human_med_000796.jsp&mid=WC0b01ac08001d1 24 (accessed 24.09.2014)
    - WO 2008 142175 A1 (ORIGINAL DOCUMENT), & WO2008142175 A1 00000000
    - FOX C.B. ET AL, "Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions", COLLOIDS AND SURFACES, B: BIOINTERFACES, (2008), vol. 65, doi:doi:10.1016/j.colsurfb.2008.03.003, pages 98 - 105, XP022710121

DOI:   http://dx.doi.org/10.1016/j.colsurfb.2008.03.003
    - internet citation http://lorien.ncl.ac.uk/ming/distil/distilop.htm
    - internet citation http://lorien.ncl.ac.uk/ming/distil/distilvle.htm
    - MAKIDON P.E. ET AL, "Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine", PLOS ONE, (200808), vol. 3, no. 8, doi:doi:10.1371/JOURNAL.PONE.0002954, pages 1 - 15, XP002676516

DOI:   http://dx.doi.org/10.1371/JOURNAL.PONE.0002954
    - NERGIZ C. ET AL, "The effect of consecutive steps of refining on squalene content of vegetable oils", J. FOOD SCI. TECHNOL., (201106), vol. 48, no. 3, pages 382 - 385
    - Costello, "Distillation an introduction", from http://www..rccostello.com/distil/distrilpri.htm, cited 18.04.2016
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.